EPIX News and Press, ESSA Pharma Inc. From 04/14/22

The following slide deck was published by ESSA Pharma Inc. in conjunction with this event. For further details see: ESSA Pharma (EPIX) Presents At Oppenheimer Healthcare Conference

ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders Canada NewsWire Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that a...

ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference Canada NewsWire South San Francisco, California and Vancouver, Canada , March 10, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical compa...

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Canada NewsWire SOUTH SAN FRANCISCO , California and VANCOUVER, Canada , March 9, 2022 /CNW/ - ESSA Pharma Inc. (" ESSA " or the " Company ") (NASDAQ: EPIX), a clin...

ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting Canada NewsWire First presentation of preclinical data for ESSA's androgen recep...

ESSA Pharma press release (NASDAQ:EPIX): Q1 GAAP EPS of -$0.21. At December 31, 2021, the Company had available cash reserves and short-term investments of $189.2 million reflecting the gross proceeds of the February 2021 financing of approximately $150.0 million and July 2020 financing of $4...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021 Canada NewsWire HOUSTON, Texas and VANCOUVER, Canada , Feb. 3, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clin...

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Canada NewsWire HOUSTON and VANCOUVER, BC , Jan. 19, 2022 /CNW/ - ESSA Phar...

ESSA Pharma (NASDAQ:EPIX): Q4 GAAP EPS of -$0.20 beats by $0.03. At September 30, 2021, the Company had available cash reserves and short-term investments of $194.9M, reflecting the gross proceeds of the February 2021 financing of approximately $150.0M and July 2020 financing of $48.9M, less ...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021 PR Newswire VANCOUVER, Canada and HOUSTON, Texas , Nov. 18, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company...